Development of a novel tumor immunotherapy targeting CD200 receptor

• Project/Area Number: 16K15291
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Immunology
• Research Institution: University of Miyazaki
• Principal Investigator: Sato Katsuaki 宮崎大学, 医学部, 教授 (40301147)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000); Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 免疫監視 / 腫瘍免疫 / 免疫抑制分子 / 抗原提示細胞 / T細胞 / 抗体療法 / 樹状細胞 / 適応免疫 / がん免疫 / 機能制御分子 / 免疫チェックポイント

Outline of Final Research Achievements

In this study, we examined the function of anti-CD200R mAb and its ability to enhance T-cell responses. We revealed that the injection with anti-CD200R mAb exhibited a specific depletion of CD200R+cells in mice. Furthermore, the injection with anti-CD200R mAb resulted in the enhancement of T-cell responses. On the other hand, we examined the anti-tumor effect of anti-CD200R mAb based on the specific depletion of CD200R+cells in tumor-bearing mice. We showed that the injection with anti-CD200R mAb caused the enhancement of T-cell responses and anti-tumor effect.